A single-center experience with pancreatic cystic neuroendocrine tumors.
Cystic component
Pancreatic neuroendocrine tumor
Survival
Journal
World journal of surgical oncology
ISSN: 1477-7819
Titre abrégé: World J Surg Oncol
Pays: England
ID NLM: 101170544
Informations de publication
Date de publication:
15 Aug 2020
15 Aug 2020
Historique:
received:
27
05
2020
accepted:
06
08
2020
entrez:
18
8
2020
pubmed:
18
8
2020
medline:
15
5
2021
Statut:
epublish
Résumé
Pancreatic neuroendocrine tumors (PNET) are rare, with a significant malignant potential. This study aimed to determine outcomes of patients with resected PNETs according to the cystic component and confirm the accuracy of preoperative staging. From 1997 to 2016, 106 patients underwent resection of PNETs, including 73 purely solid (S-PNETs, 69%), 21 mixed (M-PNETs, 20%), and 12 purely cystic lesions (C-PNETs, 11%). To ensure consistent comparisons of overall (OS) and disease-free (DFS) survival outcomes between the 3 groups, the patients were matched according to the World Health Organization (WHO) grade and tumor height. Overall, the rate of correlation between the preoperative and pathological diagnoses was low in the C-PNET group (33%, P = 0.03). None of the 24 patients (23%) with metastatic disease at the time of surgery were in the C-PNET group. Furthermore, significantly more parenchyma-sparing resections (P = 0.039) and fewer enlarged resections (P = 0.019) were achieved in the C-PNET group. C-PNET group had a significantly lower node invasion rate than the S-PNET and M-PNET groups (8% vs. 41% and 24%, P = 0.004). Although median OS was comparable in all 3 groups before (P = 0.3) and after (P = 0.18) matching, higher median DFS was observed in the C-PNET group than in the other groups after matching (P = 0.038). C-PNET was associated with a better prognosis than PNET with a solid component. The results support a wait-and-see policy in cases wherein a reliable preoperative diagnosis remains challenging.
Sections du résumé
BACKGROUND
BACKGROUND
Pancreatic neuroendocrine tumors (PNET) are rare, with a significant malignant potential. This study aimed to determine outcomes of patients with resected PNETs according to the cystic component and confirm the accuracy of preoperative staging.
METHODS
METHODS
From 1997 to 2016, 106 patients underwent resection of PNETs, including 73 purely solid (S-PNETs, 69%), 21 mixed (M-PNETs, 20%), and 12 purely cystic lesions (C-PNETs, 11%). To ensure consistent comparisons of overall (OS) and disease-free (DFS) survival outcomes between the 3 groups, the patients were matched according to the World Health Organization (WHO) grade and tumor height.
RESULTS
RESULTS
Overall, the rate of correlation between the preoperative and pathological diagnoses was low in the C-PNET group (33%, P = 0.03). None of the 24 patients (23%) with metastatic disease at the time of surgery were in the C-PNET group. Furthermore, significantly more parenchyma-sparing resections (P = 0.039) and fewer enlarged resections (P = 0.019) were achieved in the C-PNET group. C-PNET group had a significantly lower node invasion rate than the S-PNET and M-PNET groups (8% vs. 41% and 24%, P = 0.004). Although median OS was comparable in all 3 groups before (P = 0.3) and after (P = 0.18) matching, higher median DFS was observed in the C-PNET group than in the other groups after matching (P = 0.038).
CONCLUSION
CONCLUSIONS
C-PNET was associated with a better prognosis than PNET with a solid component. The results support a wait-and-see policy in cases wherein a reliable preoperative diagnosis remains challenging.
Identifiants
pubmed: 32799893
doi: 10.1186/s12957-020-01994-6
pii: 10.1186/s12957-020-01994-6
pmc: PMC7429455
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
208Références
Gastrointest Endosc. 2020 May;91(5):1095-1104
pubmed: 31881204
Surgery. 2016 Jan;159(1):302-9
pubmed: 26547726
Ann Surg Oncol. 2012 Jan;19(1):169-75
pubmed: 21761104
Eur J Surg Oncol. 2006 Jun;32(5):553-6
pubmed: 16580809
Surgery. 2011 Jul;150(1):75-82
pubmed: 21683859
World J Surg. 2015 Jun;39(6):1557-66
pubmed: 25691214
Surgery. 2016 Sep;160(3):708-13
pubmed: 27216830
Asia Ocean J Nucl Med Biol. 2019 Spring;7(2):129-140
pubmed: 31380452
J Am Soc Cytopathol. 2015 Nov - Dec;4(6):335-343
pubmed: 31051748
Neuroendocrinology. 2018;106(3):234-241
pubmed: 28586782
Int J Surg. 2015 Sep;21 Suppl 1:S44-9
pubmed: 26118611
Surgery. 2005 Jul;138(1):8-13
pubmed: 16003309
Surgery. 2012 Apr;151(4):518-25
pubmed: 22088817
J Pathol Inform. 2019 Nov 13;10:34
pubmed: 31799020
Gastroenterology. 2008 Nov;135(5):1469-92
pubmed: 18703061
J Am Coll Surg. 2008 Jun;206(6):1154-8
pubmed: 18501813
J Am Coll Surg. 2015 Apr;220(4):530-6
pubmed: 25724606
Am J Surg Pathol. 2012 Nov;36(11):1666-73
pubmed: 23073325
Lancet Oncol. 2008 Jan;9(1):61-72
pubmed: 18177818
HPB (Oxford). 2015 Jun;17(6):485-9
pubmed: 25691074
J Nucl Med. 2014 Oct;55(10):1598-604
pubmed: 25168627
Surgery. 2012 Dec;152(6):965-74
pubmed: 23102679
HPB (Oxford). 2015 Jan;17(1):38-45
pubmed: 25041879
Eur J Surg Oncol. 2019 Jan;45(1):46-51
pubmed: 29126671